22 Jan ImmPACT Bio
Posted at 20:48h
in
Sumant Ramachandra, M.D., Ph.D., CEO
April 9 | 12:00pm | Salone dei Cavalieri, Section 2
Los Angeles, CA,
(Private)
ImmPACT Bio USA, Inc., is a clinical-stage company dedicated to the discovery of transformative chimeric antigen receptor (CAR) T-cell therapies that address key biological challenges in treating cancer and autoimmune diseases. The company’s logic-gate-based CAR T-cell platforms, licensed from University of California, Los Angeles (UCLA), are specifically designed to prevent antigen escape, overcome the immunosuppressive tumor microenvironment, and deplete pathogenic B cells. The company’s technology is based on the work of pioneering UCLA scientists Yvonne Chen, Ph.D., and Antoni Ribas, M.D., Ph.D.
